Filtered By:
Source: Frontiers in Neurology
Condition: Hemorrhagic Stroke

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 496 results found since Jan 2013.

Pre-Existing Non-Disabling Encephalomalacia Confers Risk to Stroke Outcomes After Endovascular Treatment
ConclusionsA pre-existing non-disabling EM is common and safe in patients undergoing EVT. However, a contralateral EM and the large size of EM may predict an unfavorable outcome at 90 days, which should receive more attention before EVT.
Source: Frontiers in Neurology - February 11, 2022 Category: Neurology Source Type: research

A Novel Endovascular Therapy Strategy for Acute Ischemic Stroke Due to Intracranial Atherosclerosis-Related Large Vessel Occlusion: Stent-Pass-Aspiration-resCuE-Micowire-Angioplasty (SPACEMAN) Technique
ConclusionsThis study suggests that SPACEMAN exhibits a shorter operation revascularization time than the standard thrombectomy. Complications and prognosis were comparable between the two groups. The safety and efficacy of this novel technique need to be studied in larger patient series.
Source: Frontiers in Neurology - February 14, 2022 Category: Neurology Source Type: research

Elevated Serum Lactate Dehydrogenase Predicts Unfavorable Outcomes After rt-PA Thrombolysis in Ischemic Stroke Patients
ConclusionsElevated serum LDH levels predicted unfavorable clinical outcomes after intravenous thrombolysis in AIS patients.
Source: Frontiers in Neurology - April 6, 2022 Category: Neurology Source Type: research

An Optimal Animal Model of Ischemic Stroke Established by Digital Subtraction Angiography-Guided Autologous Thrombi in Cynomolgus Monkeys
ConclusionOur study may provide an optimal non-human primate model for an in-depth study of the pathogenesis and treatment of focal cerebral ischemia.
Source: Frontiers in Neurology - April 25, 2022 Category: Neurology Source Type: research

Safety and Efficacy of Tirofiban During Intravenous Thrombolysis Bridging to Mechanical Thrombectomy for Acute Ischemic Stroke Patients: A Meta-Analysis
ConclusionThe use of tirofiban during IVT bridging mechanical thrombectomy for AIS does not increase the risk of sICH and ICH in patients and reduces the risk of postoperative re-occlusion and mortality in patients within 3 months. However, this result needs to be further confirmed by additional large-sample, multicenter, prospective randomized controlled trials.Systematic Review Registrationhttp://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022297441.
Source: Frontiers in Neurology - April 29, 2022 Category: Neurology Source Type: research

Consensus clustering of gene expression profiles in peripheral blood of acute ischemic stroke patients
In this study, we adopted the consensus clustering approach to classify patients with AIS into molecular subgroups based on the transcriptomic profiles of peripheral blood, and we identified three distinct AIS molecular subgroups and 8 modules in each subgroup by the weighted gene co-expression network analysis. Remarkably, the pre-ranked gene set enrichment analysis revealed that the co-expression modules with subgroup I-specific signature genes significantly overlapped with the differentially expressed genes in AIS patients with hemorrhagic transformation (HT). With respect to subgroup II, exclusively male patients with ...
Source: Frontiers in Neurology - August 5, 2022 Category: Neurology Source Type: research

Endovascular treatment for distal basilar artery occlusion stroke
ConclusionOur study suggests that, compared with SMT, EVT is technically feasible and safe for patients with distal BAO.
Source: Frontiers in Neurology - August 9, 2022 Category: Neurology Source Type: research

Efficacy and safety of recanalization therapy for acute ischemic stroke with COVID-19: A systematic review and meta-analysis
ConclusionsCompared with COVID-19 negative AIS patients who received recanalization treatments, COVID-19 positive patients turned out to have poorer outcomes. Particular attention needs to be paid to the treatments for these COVID-19 patients to decrease mortality and morbidity. Long-term follow-up is necessary to evaluate the recanalization treatments for AIS patients with COVID-19.Systematic review registrationhttps://inplasy.com/inplasy-2022-4-0022/, identifier: INPLASY202240022.
Source: Frontiers in Neurology - August 30, 2022 Category: Neurology Source Type: research

Factors affecting physician decision-making regarding antiplatelet therapy in minor ischemic stroke
ConclusionsMany factors affect doctors' decisions regarding antiplatelet therapy, especially guidelines, age, admission SBP level, and hypertensive disease.
Source: Frontiers in Neurology - September 1, 2022 Category: Neurology Source Type: research

An overview of the evidence to guide decision-making in acupuncture therapies for early recovery after acute ischemic stroke
ConclusionsIn the acute and early recovery phases after AIS onset, acupuncture is a promising therapeutic strategy to improve the curative effect of current treatments, especially in the recovery of neurological function. Patients in the acute phase might receive XNKQ Ac, and patients in the early recovery phase might receive EA1, CA, or SA. However, considering the current certainty of evidence, a solid recommendation warrants further exploration.Systematic review registration:https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022335426.
Source: Frontiers in Neurology - October 13, 2022 Category: Neurology Source Type: research

The impact of COVID-19 pandemic on treatment delay and short-term neurological functional prognosis for acute ischemic stroke during the lockdown period
ConclusionThe COVID-19 pandemic has had remarkable impacts on the management of AIS. The pandemic might exacerbate certain time delays and play a significant role in early adverse outcomes in patients with AIS.
Source: Frontiers in Neurology - October 20, 2022 Category: Neurology Source Type: research

Impact of time between thrombolysis and endovascular thrombectomy on outcomes in patients with acute ischaemic stroke
ConclusionsIn patients with AIS, shorter IVT-ET intervals were associated with better 3-month functional outcomes. While the time-to-IVT and time-to-ET include the time until medical attention is received, the IVT-ET time delays fall entirely within the domain of medical management and thus might be easier to optimize.
Source: Frontiers in Neurology - November 2, 2022 Category: Neurology Source Type: research

Prism adaptation combined with eye movement training for unilateral spatial neglect after stroke: Study protocol for a single-blind prospective, randomized controlled trial
This study will explore the effects of 10 sessions of combined interventions (PA & EMT) on USN and functional capacity. This study has the potential to identify a new, evidence-based treatment option and provide new ideas for the treatment of USN.Ethics and disseminationThe study protocol has been approved by the Nanchong Central Hospital. Written informed consent will be obtained from all the participants. The results of this study will be disseminated to the public through scientific conferences and a peer-reviewed journal.Trial registrationChiCTR, ChiCTR2100049482. Registered on 2 August 2021, http://www.chictr.org....
Source: Frontiers in Neurology - January 5, 2023 Category: Neurology Source Type: research

Risk factors of hemorrhagic transformation in acute ischaemic stroke: A systematic review and meta-analysis
ConclusionSeveral predictors of ICH were identified, which varied by treatment type. Studies based on larger and multi-center data sets should be prioritized to confirm the results.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=268927, identifier: CRD42021268927.
Source: Frontiers in Neurology - February 20, 2023 Category: Neurology Source Type: research

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis
ConclusionsLow-dose alteplase was related to a poor functional outcome without lowering the risk of sICH, compared with standard-dose alteplase for AIS patients in China.
Source: Frontiers in Neurology - February 21, 2023 Category: Neurology Source Type: research